Skip to main content
Vivesto logo

Vivesto — Investor Relations & Filings

Ticker · VIVE ISIN · SE0000722365 LEI · 5493003TZPR4B7QO9L49 ST Manufacturing
Open in API
Filings indexed 1,069 across all filing types
Latest filing 2019-01-21 Regulatory Filings
Country SE Sweden
Listing ST VIVE

About Vivesto

https://www.vivesto.com/en/

Vivesto is a specialty pharmaceutical company focused on drug development in oncology. The company aims to provide new therapeutic options for patients suffering from hard-to-treat cancers where significant medical needs exist. Its research and development efforts are centered on creating innovative treatments and enhancing the intravenous delivery of established and novel drugs. The company's lead product is Apealea, a formulation of the cancer drug paclitaxel.

Recent filings

Filing Released Lang Actions
Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled
Regulatory Filings Classification · 95% confidence The document explicitly announces the cancellation of an Extraordinary General Meeting (EGM) that was scheduled for January 25, 2019. This action relates to shareholder meetings and voting procedures, specifically concerning a request from a major shareholder (Arwidsro) regarding board composition and warrant disputes. While it involves a general meeting, the core action is the cancellation of the meeting itself, which is a procedural step related to shareholder governance. The closest fit among the provided codes is DVA (Declaration of Voting Results & Voting Rights Announcements), as EGMs are primarily for voting, or potentially RNS (Regulatory Filings) as a general announcement. However, since the document details the context of the EGM request and its subsequent cancellation, it is a direct announcement concerning the mechanics of a shareholder vote/meeting. Given the options, DVA covers voting results/rights announcements, and while this is a cancellation, it is highly related to the meeting process. Alternatively, since it is a formal announcement about a corporate action related to a shareholder meeting, and not the results themselves, RNS is a strong fallback. Given the context of shareholder meetings and voting rights, DVA is slightly more specific than the general RNS, but since it is not a 'result' but a 'cancellation', I will lean towards RNS as the most appropriate general regulatory announcement category for this specific procedural update, especially since AGM-R is for materials *shared during* the meeting. The document is short and appears to be a press release announcing the cancellation, fitting the RPA/RNS criteria if it were just linking to a report, but here it *is* the announcement itself. I will classify it as RNS as it is a general regulatory announcement regarding corporate governance procedure.
2019-01-21 English
Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled
Delisting Announcement Classification · 99% confidence The document is a press release announcing the cancellation of an extraordinary general meeting (EGM) scheduled for January 25, 2019. The content revolves around shareholder requests, board composition disputes, and the formal decision to cancel the meeting. While EGMs involve shareholder voting, this document is an announcement *about* the meeting's status, not the official voting results (DVA) or the proxy materials (PSI). Since it is a formal announcement regarding corporate governance and shareholder meetings, and it doesn't fit neatly into the primary financial report categories (10-K, IR, ER), it falls best under the general regulatory announcement category, RNS, or potentially AGM-R if the EGM is treated similarly to an AGM for classification purposes. Given the context of corporate governance actions and announcements, RNS (Regulatory Filings) is the most appropriate general catch-all for significant, non-financial, non-standard announcements. However, since the core subject is a General Meeting, AGM-R (AGM Information) is a strong candidate, even though it's a cancellation notice. Given the specific nature of the event (General Meeting), AGM-R is slightly more precise than the generic RNS, as it relates directly to shareholder meeting administration.
2019-01-21 English
Oasmia meddelar att den extra bolagsstämman den 25 januari 2019 ställs in
AGM Information Classification · 95% confidence The document is a press release announcing the cancellation of an Extraordinary General Meeting (EGM) scheduled for January 25, 2019. While it concerns a general meeting, the core action is an announcement about the meeting's status (cancellation), not the results of a vote (DVA) or the presentation materials for the meeting itself (AGM-R). Since it is a formal announcement regarding a corporate action related to shareholder meetings, and given the available codes, it most closely relates to the context of general meetings. However, none of the codes perfectly capture 'Cancellation of EGM Announcement'. Given the context of shareholder meetings and governance, AGM-R (AGM Information) is the closest fit among the specific meeting-related codes, although it is an announcement *about* the meeting rather than the meeting materials. Alternatively, RNS (Regulatory Filings) is a strong fallback for general regulatory announcements. Since the document explicitly discusses the cancellation of a meeting called by shareholders and involving board composition discussions, and it is a formal public disclosure, I will classify it as AGM-R as it directly pertains to the AGM process, even if it's a cancellation notice, and it is a specific corporate event announcement.
2019-01-21 Swedish
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding percentage for a specific holder (Avanza Bank Holding AB for Försäkringsaktiebolaget Avanza Pension) in the issuer (Vivesto AB). It explicitly mentions 'Reason for major shareholding notification Buy' and shows the resulting distribution of total holdings crossing a threshold ('Flaggning sker för passerat tröskelvärde'). This structure and content directly correspond to a notification regarding changes in significant share ownership, which maps to the Major Shareholding Notification category.
2019-01-15 English
European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information
Regulatory Filings Classification · 95% confidence The document is a press release from Oasmia Pharmaceutical AB announcing that the European Medicines Agency (EMA) has validated a type II variation application to add efficacy data for their drug Apealea to the product information. It details clinical trial results (PFS, OS) and provides timelines for the EMA's opinion. The text concludes with a note stating: "This information is information that Oasmia Pharmaceutical AB is obliged to make public pursuant to the EU Market Abuse Regulation." and includes an 'Attachment' link. This structure strongly suggests a mandatory regulatory disclosure that is not a full financial report (10-K, IR) or a specific shareholder vote result (DVA). Since it is a general announcement of material information required by regulation (EU Market Abuse Regulation), and it doesn't fit neatly into specific categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), the most appropriate fallback category is Regulatory Filings (RNS). It is not an Earnings Release (ER) as it focuses on regulatory submission status and clinical data, not period-end financial results.
2019-01-15 English
Europeiska läkemedelsmyndigheten (EMA) har validerat Oasmia Pharmaceutical AB’s ändringsansökan om att lägga till effektresultat till den godkända produktinformationen för Apealea®
Regulatory Filings Classification · 95% confidence The document is a press release dated 2019-01-15, titled "PRESSMEDDELANDE" (Press Release) in Swedish. It announces that the European Medicines Agency (EMA) has validated Oasmia Pharmaceutical AB's application to add efficacy results for their drug Apealea® to the approved product information. The text details clinical trial data (subgroup analysis results, hazard ratios, median survival times) related to this regulatory submission. This type of announcement, detailing progress in regulatory submissions, clinical data updates, or general corporate news outside of mandatory periodic financial reports (like 10-K or IR), typically falls under general regulatory announcements or investor relations updates. Since it is a formal announcement about a regulatory/clinical event and not a full financial report, an earnings release, or a management discussion, it best fits the 'Regulatory Filings' (RNS) category as a general regulatory announcement, or potentially 'LTR' if it were about legal proceedings, but here it is about a drug approval process. Given the options, 'RNS' (Regulatory Filings - general regulatory announcements and fallback) is the most appropriate classification for a press release detailing regulatory validation and clinical data submission progress, especially since it is not a specific financial report type like 10-K or ER.
2019-01-15 Swedish

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.